logo
logo
HealthEquity, Inc.

HealthEquity, Inc.

NASDAQ•HQY
CEO: Mr. Jon Kessler
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2014-07-31
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.
連絡先情報
15 West Scenic Pointe Drive, Suite 100, Draper, UT, 84020, United States
801-727-1000
www.healthequity.com
時価総額
$6.33B
PER (TTM)
32.8
53.6
配当利回り
--
52週高値
$116.65
52週安値
$72.99
52週レンジ
1%
順位31Top 21.6%
5.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2026 データ

売上高

$322.16M+7.23%
直近4四半期の推移

EPS

$0.60+817.43%
直近4四半期の推移

フリーCF

$137.79M+77.37%
直近4四半期の推移

2026 Q3 決算ハイライト

主なハイライト

Net Income Soars 135% Nine-month net income reached $165.5M, reflecting a massive 135% increase over prior year period results.
Total Revenue Up Ten Percent Total revenue for nine months hit $978.8M, growing 10% driven by custodial and interchange increases.
Operating Cash Flow Strong Net cash provided by operating activities totaled $339.2M for nine months, showing $75.1M improvement.
HSA Assets Exceed $34 Billion Total HSA Assets grew 15% to $34.4B as of October 31, 2025, driven by investment appreciation.

リスク要因

Cybersecurity Litigation Exposure Subject to multiple legal actions following 2025 security incident; potential loss amount cannot be reasonably estimated.
Interest Rate Fluctuation Risk Custodial revenue exposure exists from sustained shifts in prevailing interest rates impacting HSA cash yields.
Regulatory Environment Uncertainty Changes in tax policy and state privacy laws may adversely affect business operations in unpredictable ways.
Competition Resource Disparity Direct competitors, including large banks, devote greater resources to product development and service support.

見通し

Investing in Technology Modernization Continuing investment in proprietary technology architecture to enhance security, platform infrastructure, and service delivery.
Expect Reduced Tax Payments Corporate income tax payments expected to be significantly reduced due to accelerated deductions from new legislation.
Liquidity Meets Near-Term Needs Existing cash, equivalents, and revolving credit facility sufficient to meet operating and capital expenditure requirements for 12 months.
Focus on Product Breadth Strengthening value proposition by integrating HSA offerings with complementary CDBs for single-source provider status.

同業比較

売上高 (TTM)

Molina Healthcare, Inc.MOH
$45.43B
+11.7%
DaVita Inc.DVA
$13.64B
+6.5%
Henry Schein, Inc.HSIC
$12.94B
+3.5%

粗利益率 (最新四半期)

Corcept Therapeutics IncorporatedCORT
97.8%
-0.6pp
Jazz Pharmaceuticals plcJAZZ
77.1%
-12.3pp
Hims & Hers Health, Inc.HIMS
73.8%
-5.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
GH$13.29B-32.2151.9%103.9%
PEN$13.29B80.713.1%12.4%
GMED$11.67B27.710.0%2.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.1%
緩やかな成長
4四半期純利益CAGR
25.2%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年3月17日
|
EPS:$0.89
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2026

    会計期末: 2025年10月31日|提出日: 2025年12月3日|
    売上高: $322.16M+7.2%
    |
    EPS: $0.60+817.4%
    予想を下回る

  • Form 10-Q - Q2 2026

    会計期末: 2025年7月31日|提出日: 2025年9月2日|
    売上高: $325.84M+8.6%
    |
    EPS: $0.69+68.3%
    予想を下回る

  • Form 10-Q - Q1 2026

    会計期末: 2025年4月30日|提出日: 2025年6月3日|
    売上高: $330.84M+15.0%
    |
    EPS: $0.62+87.9%
    予想を下回る

  • Form 10-K - FY 2025

    会計期末: 2025年1月31日|提出日: 2025年3月18日|
    売上高: $1.20B+20.0%
    |
    EPS: $1.11+70.8%
    予想を上回る

  • Form 10-Q - Q3 2025

    会計期末: 2024年10月31日|提出日: 2024年12月9日|
    売上高: $300.43M+20.5%
    |
    EPS: $0.07-61.5%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2024年7月31日|提出日: 2024年9月3日|
    売上高: $299.93M+23.1%
    |
    EPS: $0.41+241.7%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2024年4月30日|提出日: 2024年6月3日|
    売上高: $287.60M+17.7%
    |
    EPS: $0.33+560.0%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年1月31日|提出日: 2024年3月22日|
    売上高: $999.59M+16.0%
    |
    EPS: $0.65+309.7%
    予想を上回る